Skip directly to content

Guías Internacionales de Manejo


Las guías soportan el uso de LYRICA como un tratamiento de primera línea con evidencia nivel A 1

 

Referencias:

  1. Pop-Busui R. Boulton AJM. Feldman EL, et al Diabetic neuropathy. A position statement by the American Diabetes Association. Diabetes Care 2017;40:136-154
  2. Dworkin RH, O’Connor AB, Audette J, et al, Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc. 2010;85(3)(suppl);S3-S14.
  3. Bril V. England J, Franklin GM, et al. Evidence-bases guideline: Tratment of painful diabetic neuropathy; report of the American Academy of Neurology, the Amercian Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation . Neurology 2011:76:1758-1765
  4. Moulin DE, Boulanger A. Clark AJ, et al. Pharmacological management of chronic neuropathic pain; Revised consensus statement from Canadian Pain Society. Pain Res Manage 2014;19(6)328-335
  5. Finnerup NB, Attal N, Haroutounian S. et aL Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015:14:162-173.
  6. Attal N. Cruccu G. Baron R. et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010:17:1113-1123
  7. D’Arcy Y, McCarberg B, Parsons B, Behar R, Thorpe A, Alexander A. Pregabalin for the treatment of neuropathic pain: a narrative review for primary care providers. Curr Med Res Opin 2017;33(8):1353-1359
  8. Pregabalina. Documento local del productoPregabalin(Lyrica Alond)_LLD_CDS v 18.0_01May2014.

 

 

Volver a menú
Este material es de uso exclusivo para el cuerpo médico. Información disponible en la dirección médica de Pfizer S.A.S
© Pfizer S.A.S. Todos los derechos reservados – Prohibida su reproducción total o parcial sin autorización del titular.
Código Interno: PP-LYR-COL-0252